BiotechTube

FORTEO + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bone Loss

Conditions

Bone Loss, Periodontitis

Trial Timeline

Aug 1, 2004 → Jul 1, 2009

NCT ID
NCT00277706

About FORTEO + Placebo

FORTEO + Placebo is a phase 1 stage product being developed by Eli Lilly for Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00277706. Target conditions include Bone Loss, Periodontitis.

What happened to similar drugs?

16 of 20 similar drugs in Bone Loss were approved

Approved (16) Terminated (1) Active (4)
✅Reclast (ZOL446, zoledronic acid)NovartisApproved
✅zoledronic acidNovartisApproved
✅Zoledronic acidNovartisApproved
✅Disodium pamidronate + PlaceboNovartisApproved
✅Zoledronic acidNovartisApproved
✅Zoledronic acidNovartisApproved
✅PamidronateNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00277706Phase 1Completed

Competing Products

20 competing products in Bone Loss

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
EnzalutamideAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
MerestinibEli LillyPhase 1
21
Arzoxifene + PlaceboEli LillyPhase 3
40
TanezumabEli LillyPhase 3
40
Anastrozole + TamoxifenAstraZenecaPhase 3
40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
Zoledronic acid + LetrozoleNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
NilotinibNovartisPhase 1
29
Reclast (ZOL446, zoledronic acid)NovartisApproved
43
Zoledronic acidNovartisPhase 3
32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
40
zoledronic acidNovartisPhase 1
29
Ruxolitinib continuous therapyNovartisPhase 2
39
zoledronic acidNovartisApproved
43